Department of Community Health, Advanced Medical and Dental Institute
Kepala Batas, Pulau Pinang, 13200, Malaysia
NCT Number: NCT06544252
The objective of this research is to determine the influence of low and high glycemic index Malaysian pre-exercise mixed meals on endurance exercise performance in a hot-humid environment. Glycemic index (GI) is a method used to classify CHO-containing foods based on their influence on postprandial blood glucose when compared to the response on blood glucose after ingesting the same amount of CHO from a reference food (glucose or bread). Low GI (LGI) foods are digested and absorbed more slowly as compared to high GI (HGI) foods, resulting in a stable rise in blood glucose levels.
The participants were trained male endurance long-distance runners. On the day of experimental trials, they consumed pre-exercise rice-based mixed meal, either LGI or HGI 3 hours before endurance running exercise. After that, they ran for 45 minutes at constant running speed equivalent to 70% VO2peak, followed by 10km time-trial. The respiratory gases, blood measures, rectal and skin temperature were measured throughout the running test.
Looking for future studies?
Notify Me18 year–35 year
Male
Interventional
Not applicable
Kepala Batas, Pulau Pinang, 13200, Malaysia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The mixed meal consisted of Basmati rice, chicken, and green-leafy vegetables. The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
The mixed meal consisted of fragrant rice, chicken, and green-leafy vegetables.The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
Time frame: Up to 1 hour
The participant was clearly instructed to complete the 10 km time-trial as quickly as possible. The 10 km time-trial commenced with a 30-s rolling start to the participant's 70% V̇O2peak speed, after which the participant could freely adjust the speed. Throughout the 10 km time-trial, the prevailing running velocity and time-lapse were blinded to the participant, and only information on the distance covered at 1 km intervals was verbally provided to the participant.
Time frame: Up to 2 hours
A portable gas analyser (K5, COSMED, Italy) was used to measure the respiratory gas exchange. Prior to each experimental session, the device was calibrated according to the procedures outlined in the manufacturer's instructions. The mixing chamber measurements were performed for V̇O2, V̇CO2, and respiratory exchange ratio (RER) and were measured continuously throughout exercise trials. The average values for V̇O2 (L.min-1) and V̇CO2 (L.min-1) were calculated over the last 30-s of each 15-min interval during SS running and each 1 km of 10 km time-trial.
Whole-body rates of CHO and fat oxidation (g.min-1) were calculated using intensity-dependent equations for moderate to high-intensity exercise (50 - 75% V̇O2max) that assume negligible protein contribution to energy expenditure (Jeukendrup and Wallis 2005):
CHO oxidation (g.min-1): (4.210 x V̇CO2) - (2.962 x V̇O2) Fat oxidation (g.min-1): (1.695 x V̇O2) - (1.701 x V̇CO2)
Time frame: Up to 5 hours
The capillary blood was sampled for blood glucose via a finger prick using a sterile, single-use lancet (Accu-Check Safe-T-Pro Plus; Roche Diagnostics) during fasting state (before meal consumption), postprandial period (at 15, 30, 60, 90, 120, 180-min intervals), steady-state running (at 10, 30, 45-min intervals), time-trial 10km running performance (at 5, 10km marks).
Time frame: Up to 5 hours
The venous blood was sampled for insulin using 22G IV catheter insertion (Surflo IV Catheter, Terumo Med Corporation, Eklton, MD., USA) during fasting state (before meal consumption), postprandial period (at 30, 90, 180-min intervals), steady-state running (at 10, 30, 45-min intervals), time-trial 10km running performance (at 10 km marks).
Time frame: Up to 5 hours
The venous blood was sampled for cortisol using 22G IV catheter insertion (Surflo IV Catheter, Terumo Med Corporation, Eklton, MD., USA) during fasting state (before meal consumption), postprandial period (at 180-min interval), steady-state running (at 45-min interval), time-trial 10km running performance (at 10 km marks).
Time frame: Up to 2 hours
The venous blood was sampled for lactate using 22G IV catheter insertion (Surflo IV Catheter, Terumo Med Corporation, Eklton, MD., USA) at postprandial period (at 180-min interval), steady-state running (at 10, 45-min intervals), time-trial 10 km running performance (at 10 km marks).
Time frame: Up to 2 hours
Heart rate was recorded using heart rate monitor (Garmin HRM-Run®; Olathe, KS, USA) throughout the running test.
Time frame: Up to 2 hours
Rectal temperature (Tre), and skin temperature (Tsk) were continuously measured throughout the running exercise. Tre was measured by self-inserting a disposable thermistor probe (YSI 400 series, Mallinckrodt Medical, Kansas City, Mo., USA) 12 cm beyond the anal sphincter. Tsk was assessed at four distinct sites (left shoulder, left chest, right mid-thigh, and right mid-shin) using iButton temperature sensors (Maxim Integrated Products,Sunnyvale, CA., USA).
Universiti Sains Malaysia
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details